Want to see INIS full AI Analyst Report?
INIS Stock Chart & Stats
$0.06
<$0.01(12.90%)
At close: 4:00 PM EDT
$0.06
<$0.01(12.90%)
Day’s Range― - ―
52-Week Range$0.05 - $0.11
Previous CloseN/A
Volume45.00K
Average Volume (3M)23.28K
Market Cap
$34.40M
Enterprise Value$45.05
Total Cash (Recent Filing)$1.20M
Total Debt (Recent Filing)$9.21M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1723.63
Shares Outstanding529,154,200
10 Day Avg. Volume11,948
30 Day Avg. Volume23,282
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)8.74
Price to Sales (P/S)2.47
P/FCF Ratio375.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Refocus On IsotopesExiting the uranium-fuel development project could sharpen strategic focus on the company’s established radioisotope activities. If completed, the transaction may direct management attention and capital toward medical and industrial isotope growth, potentially improving execution over the next several quarters.
Expanded Nuclear Medicine Technology PortfolioAdding imaging software, hardware, intellectual property and regulatory approvals broadens the company’s nuclear medicine offering beyond isotope production alone. This could support more integrated customer solutions and strengthen competitive positioning if the acquired technologies achieve regulatory and sales milestones.
Improved Capital FlexibilityExtending maturities and removing liens can reduce near-term balance-sheet pressure and give management more flexibility to allocate resources. The revised conversion provisions may also support restructuring of obligations, although the benefits depend on the company managing its capital structure effectively.
Bears Say
Sharp Profitability DeteriorationThe combination of declining revenue and deeply negative operating results indicates that the business currently lacks consistent earnings power. Even if part of the reported loss reflects a one-time or non-operating item, the swing from near break-even to substantial losses weakens financial resilience.
Elevated And Volatile LeverageHigh debt relative to equity leaves limited capacity to absorb operating setbacks and increases dependence on refinancing or other capital actions. The extreme 2025 reading adds uncertainty to the capital structure and could constrain investment in isotope growth while obligations remain elevated.
Inconsistent Cash GenerationRecent cash consumption means the company is not currently funding operations reliably from internal generation. Prior positive periods show that cash generation is possible, but the large year-to-year swings reduce confidence in self-funding, limit investment flexibility, and heighten reliance on financing.
International Isotopes News
INIS FAQ
What was International Isotopes’s price range in the past 12 months?
International Isotopes lowest stock price was $0.04 and its highest was $0.11 in the past 12 months.
What is International Isotopes’s market cap?
International Isotopes’s market cap is $34.40M.
When is International Isotopes’s upcoming earnings report date?
International Isotopes’s upcoming earnings report date is Nov 17, 2026 which is in 44 days.
How were International Isotopes’s earnings last quarter?
International Isotopes released its earnings results on Aug 13, 2026. The company reported -$0.002 earnings per share for the quarter.
Is International Isotopes overvalued?
According to Wall Street analysts International Isotopes’s price is currently Overvalued.
Does International Isotopes pay dividends?
International Isotopes does not currently pay dividends.
What is International Isotopes’s EPS estimate?
International Isotopes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does International Isotopes have?
International Isotopes has 529,154,200 shares outstanding.
What happened to International Isotopes’s price movement after its last earnings report?
International Isotopes reported an EPS of -$0.002 in its last earnings report. Following the earnings report the stock price went up 4.688%.
Which hedge fund is a major shareholder of International Isotopes?
Currently, no hedge funds are holding shares in INIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
International Isotopes
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, accurate patient positioning, and for calibrating or testing the performance of dose-measuring equipment within the nuclear pharmacy industry. This segment's product range includes flood sources, dose calibrators, rod sources, flexible and rigid rulers, precision spot and pen point markers, and numerous custom-designed items. The Cobalt Products division processes bulk cobalt, fabricates cobalt capsules for use in radiation therapy and diverse industrial applications, and is involved in the recycling of depleted cobalt sources. Through its Radiochemical Products segment, Radnostix develops and supplies a variety of highly pure radiochemicals, along with the generic drug product sodium iodide I-131, serving medical, industrial, and research applications. The Radiological Services segment offers specialized services such as the safe disposal of flood sources and the intricate processing of gemstones. Finally, the Fluorine Products segment focuses on producing small-scale, high-purity fluoride gas samples for qualification in various industrial applications. It also undertakes the development of critical laboratory and analytical processes required to support a planned uranium de-conversion and fluorine extraction facility. Radnostix, Inc. distributes its products directly to end-users as well as through a network of distributors. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho.
Technical Analysis
Ownership Overview
13.32% Insiders
<0.01% Other Institutional Investors
86.68% Public Companies and
Individual Investors